Tesamorelin raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-06-28. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
With the invention of the Geiger gaseous ionization detector in 1913, which became the Geiger-Müller gaseous ionization detector in 1928 - named after the physicists Hans Geiger (1882-1945) and Walther Müller (1905-1979) - the individual particles or quanta of ionizing radiation could be detected and measured. Detectors developed later, such as proportional counters or scintillation counters, which not only "count" but also measure energy and distinguish between types of radiation, also became important for radiation protection. Scintillation measurement is one of the oldest methods of detecting ionizing radiation or X-rays; originally, a zinc sulfide screen was held in the path of the beam and the scintillation events were either counted as flashes or, in the case of X-ray diagnostics, viewed as an image. A scintillation counter known as a spinthariscope was developed in 1903 by William Crookes (1832-1919) and used by Ernest Rutherford (1871-1937) to study the scattering of alpha particles from atomic nuclei.
== Associated conditions == Diseases of the pituitary, the gland that produces, among others, the hormone ACTH Hypopituitarism, the hyposecretion of ACTH in the pituitary, leading to secondary adrenal insufficiency (a form of hypocorticism) Addison's disease, the primary adrenal insufficiency (another form of hypocorticism) Cushing's syndrome, hypercorticism, one of the causes is hypersecretion of ACTH Small cell carcinoma, a common cause of ACTH secreted ectopically Congenital adrenal hyperplasia, diseases in the production of cortisol Nelson's syndrome, the rapid enlargement of the ACTH producing pituitary after the removal of both adrenal glands Adrenoleukodystrophy, can be accompanied by adrenal insufficiency West syndrome ("infantile spasms"), a disease where ACTH is used as a therapy Postorgasmic illness syndrome (POIS), through production of tyrosine hydroxylase and dopamine β-hydroxylase, which two enzymes comprise the biochemical mechanism by which norepinephrine and epinephrine are produced. Critical illness-related corticosteroid insufficiency DAVID syndrome, a genetic disorder that is characterized by adrenocorticotropic hormone deficiency combined with common variable immunodeficiency and hypogammaglobulinemia.
== Interactions == Besides integrin, fibronectin binds to many other host and non-host molecules. For example, it has been shown to interact with proteins such fibrin, tenascin, TNF-α, BMP-1, rotavirus NSP-4, and many fibronectin-binding proteins from bacteria (like FBP-A; FBP-B on the N-terminal domain), as well as the glycosaminoglycan, heparan sulfate. pUR4 is a recombinant peptide that is known to inhibit the polymerization of fibronectin in a number of cell types including fibroblasts and endothelial cells. Fibronectin has been shown to interact with:
Venlafaxine was originally marketed as Effexor in most of the world; generic venlafaxine has been available since around 2008 and extended-release venlafaxine has been available since around 2010. Venlafaxine is sold under many brand names worldwide. In some countries, Effexor is marketed by Viatris after Upjohn was spun off from Pfizer.
Sources: en.wikipedia.org
Manifesting, in addition, that Peru was "a nation without blood, without probity and without sincere inclinations to the ally that had agreed to the alliance "with the deliberate and sole purpose of ensuring its preponderance in the Pacific over Chile." Later, the famous writer from Santa Cruz, René Gabriel Moreno, would come out in defense of Arce for coincidences in his anti-Peruvian positions in Bolivian geopolitics. Referring to Campero, Moreno writes «Is it not well remembered that this man shouted War! War! While he was quietly contemplating the war efforts of his ally Peru?». Like Arce, Moreno is clearly opposed to any understanding or pact with Peru and maintains that Argentina, both the government and the people, were leaning in favor of Bolivia, repudiating, at the same time, Campero's strange and provocative attitude.In Arce's vision, Chile is presented as a vigorous country full of civic virtues that predicted its democratic culture, as well as a Great National Conscience, compared to Peru and Bolivia, weak and in the process of social disintegration due to their lack of modernity. Already in the middle of the War with Chile, Aniceto Arce warned, as the only prospect of peace, an explicit proximity to Chile, turning his back on Peru. The proposal meant breaking the allied front in exchange for the annexation of Tacna and Arica, it meant ultimately betraying the pact made with Peru. Undoubtedly, Aniceto Arce had strong common interests with the British financiers who maintained his headquarters in Chile.
A cloud laboratory is a heavily automated, centralized research laboratory where scientists can run an experiment from a computer in a remote location. Cloud laboratories offer the execution of life science research experiments under a cloud computing service model, allowing researchers to retain full control over experimental design. Users create experimental protocols through a high-level API and the experiment is executed in the cloud laboratory, with no need for the user to be involved. Cloud labs reduce variability in experimental execution, as the code can be interrogated, analyzed, and executed repeatedly. They democratize access to expensive laboratory equipment while standardizing experimental execution, which could potentially help address the replication crisis—what might before have been described in a paper as "mix the samples" is replaced by instructions for a specified machine to mix at a specified rpm rate for a specified time, with relevant factors such as the ambient temperature logged. They also reduce costs by sharing capital costs across many users, by running experiments in parallel, and reducing instrument downtime. Finally, they facilitate collaboration by making it easier to share protocols, data, and data processing methods through the cloud.
== Synthesis == Clicked peptide polymers are prepared by the azide-alkyne Huisgen cycloaddition also called the click reaction; which is commonly used in bioconjugation reactions to link molecules together with a stable triazole bridge. Peptide based polymers are produced from a cycloaddition variant of step-growth polymerization. The monomers used in this polymerization are oligopeptides with terminal azide and terminal alkyne groups
Dense connective tissue, also called dense fibrous tissue, is a type of connective tissue with fibers as its main matrix element. The fibers are mainly composed of type I collagen. Crowded between the collagen fibers are rows of fibroblasts, fiber-forming cells, that generate the fibers. Dense connective tissue forms strong, rope-like structures such as tendons and ligaments. Tendons attach skeletal muscles to bones; ligaments connect bones to bones at joints. Ligaments are more stretchy and contain more elastic fibers than tendons. Dense connective tissue also make up the lower layers of the skin (dermis), where it is arranged in sheets. In addition, the sclera contains dense connective tissue
=== Numbers and habitats of major phyla === The following table lists estimated numbers of described extant species for the major animal phyla, along with their principal habitats (terrestrial, fresh water, and marine), and free-living or parasitic ways of life. Species estimates shown here are based on numbers described scientifically; much larger estimates have been calculated based on various means of prediction, and these can vary wildly. For instance, around 25,000–27,000 species of nematodes have been described, while published estimates of the total number of nematode species include 10,000–20,000; 500,000; 10 million; and 100 million. Using patterns within the taxonomic hierarchy, the total number of animal species—including those not yet described—was calculated to be about 7.77 million in 2011.
Sources: en.wikipedia.org
==== Inflammatory problems ==== High incidences of coexisting inflammatory disorders suggest a correlation between connective tissue disorders and the development of such aforementioned conditions. Inflammatory bowel diseases such as Crohn's disease, ulcerative colitis and celiac disease are more common in EDS patients when compared to control groups. Of note, patients who are already diagnosed with an inflammatory bowel disorder are not necessarily likely to develop symptoms of a connective tissue disorder, as the two have separate but not totally confounding etiologies. Eosinophilic esophagitis, an inflammatory condition characterized by allergic-type reactions to various foods and chemicals and extensive esophageal remodeling, is eight times more likely in patients with connective tissue disorders when compared to patients without.
Per Mendeleev's nomenclature for unnamed and undiscovered elements, flerovium is sometimes called eka-lead. In 1979, IUPAC published recommendations according to which the element was to be called ununquadium (symbol Uuq), a systematic element name as a placeholder, until the discovery of the element is confirmed and a permanent name is decided on. Most scientists in the field called it "element 114", with the symbol of E114, (114) or 114. Per IUPAC recommendations, the discoverer(s) of a new element has the right to suggest a name. After IUPAC recognized the discovery of flerovium and livermorium on 1 June 2011, IUPAC asked the discovery team at JINR to suggest permanent names for the two elements. The Dubna team chose the name flerovium (symbol Fl), after Russia's Flerov Laboratory of Nuclear Reactions (FLNR), named after Soviet physicist Georgy Flyorov (also spelled Flerov); earlier reports claim the element name was directly proposed to honour Flyorov. In accordance with the proposal received from the discoverers, IUPAC officially named flerovium after Flerov Laboratory of Nuclear Reactions, not after Flyorov himself. Flyorov is known for writing to Joseph Stalin in April 1942 and pointing out the silence in scientific journals in the field of nuclear fission in the United States, Great Britain, and Germany. Flyorov deduced that this research must have become classified information in those countries. Flyorov's work and urgings led to the development of the USSR's own atomic bomb project.
doi:10.1353/sor.2006.0010. S2CID 143149001. Andrew D. Black (Fall 2007). ""The War on People": Reframing "The War on Drugs" by Addressing Racism Within American Drug Policy Through Restorative Justice and Community Collaboration". University of Louisville Law Review. 46 (1): 177–197. Veda Kunins, Hillary; Bellin, Eran; Chazotte, Cynthia; Du, Evelyn; Hope Arnsten, Julia (March 2007). "The effect of race on provider decisions to test for illicit drug use in the peripartum setting". Journal of Women's Health. 16 (2): 245–355. doi:10.1089/jwh.2006.0070. PMC 2859171. PMID 17388741. Beckett, Katherine (June 2008). "Drugs, Data, Race and Reaction: A Field Report". Antipode. 40 (3): 442–447. Bibcode:2008Antip..40..442B. doi:10.1111/j.1467-8330.2008.00612.x. Fellner, Jamie (2009). "Race, Drugs, and Law Enforcement in the United States". Stanford Law & Policy Review. 20 (2): 257–291.
(2026) provide the radiocarbon ages of fossils of Palaeoloxodon naumanni from Honshu and Shikoku (Japan), determine the last appearance date of the species to be 36,400–35,700 calibrated years before present, and interpret the fossil record as indicative of short coexistence of the species with Upper Paleolithic humans and its likely extinction at 35,000-33,000 calibrated years before present. Evidence from the study of the long bones of adult Palaeoloxodon tiliensis and juvenile Palaeoloxodon falconeri, indicating that bones of the former species were not scaled-down version of bones of its mainland ancestors but rather included a combination of ancestral traits, adaptations associated with a graviportal lifestyle and juvenile-like characteristics, is presented by Bader, Göhlich & Houssaye (2026). Evidence from the study of the straight-tusked elephant specimen from Middle Pleistocene site of Contrada Monticelli (Apulia, Italy) and other specimens of straight-tusked elephants and Mammuthus meridionalis from the Lower and Middle Pleistocene of Italy, indicating that the majority of purported morphological characters differentiating Mammuthus and Palaeoloxodon are not reliable when intraspecific variability is taken into consideration, is presented by Stefanelli et al. (2026). A study on the anatomy and life history of the woolly mammoth specimen from Niederweningen (Switzerland) that was the first scientifically described perinatal mammoth individual is published by Scarborough et al. (2026). Moreland et al.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.